Comparison
While Exenatide is used for type 2 diabetes treatment to improve glycemic control and modestly reduce body weight through GLP-1–like insulinotropic and glucagonostatic effects6768, Retatrutide is an investigational agent that produces very large body-weight reductions in early trials by simultaneously engaging GLP-1R, GIPR, and GCGR to enhance satiety, energy expenditure, and glycemic control2575.
While Exenatide works as a 39-amino-acid exendin-4 peptide originally isolated from Gila monster venom that acts as a long-acting GLP-1 receptor agonist resistant to DPP-4 degradation67, Retatrutide is a triple incretin agonist peptide derived from a GIP backbone and engineered to activate GLP-1, GIP, and glucagon receptors, with non-natural residues and fatty-acid conjugation that confer long half-life and balanced multi-receptor signaling256575.
Exenatide is 39 amino acids long, whereas Retatrutide is the same length as it has a length of 39 amino acids. Exenatide is made up of a sequence of sequence data not available in the current dataset. Retatrutide is made up of a sequence of sequence data not available in the current dataset.
Exenatide
Not assigned in the current dataset.
Retatrutide
Not assigned in the current dataset.